Cwell - You're exactly right. In my strong opinion, ScripsAmerica will be light years ahead of the information expressed in the Q4 report. Sure, there will be plenty of historic items on which to focus lots of negative opinions. And if folks on the sidelines intend to base their investment decision solely on the Q4 report, they may not want to join us. But of course, it doesn't take a rocket scientist to realize what Scrips is building based on all of the reported events that have occurred since 12/31/13. Indeed, all of the longterm holders have always known that Scrips is a 2014 and beyond story and that 2013 was a year of transformation and development.
Just to be sure folks have been living in a cave since 12/31/13, here are some things we have since learned about ScripsAmerica: (1) the January revenues from WholesaleRX were 62% over the prior month; (2) the company added another revenue stream that generated $57K in its first few days (compounding pharmacy); (3) RapiMed product approval in Hong Kong; (4) company is paying off remaining toxic notes and will not take on additional toxic paper. By the time the historical financial report hits, I anticipate even more positive news.
I'm very much looking forward to March Madness!
Market Data 
Markets 
AI
